Development of a tropoelastin-binding MR contrast agent for in vivo imaging of impaired elastogenesis in atherosclerosis
© Phinikaridou et al; licensee BioMed Central Ltd. 2015
Published: 3 February 2015
Elastin is a primary component of the vessel wall and present in all elastic vessels such as the aorta and the pulmonary artery. Elastogenesis begins with the synthesis and secretion of the soluble precursor tropoelastin that becomes cross-linked into insoluble elastin. Under normal conditions cross-linked elastin is the only form of the molecule present in the vessel wall whereas tropoelastin is absent. Conversely, under pathological conditions including atherosclerosis and aortic aneurysms elastogenesis resumes and tropoelastin molecules accumulate in the vessel wall. We developed a novel tropoelastin-binding MRI contrast-agent that would allow 1) specifically bind to tropoelastin but not to cross-linked mature elastin to allow 2) detection of pathologic elastogenesis that occurs in atherosclerosis and 3) minimizing non-specific signal from endogenously present mature elastin.
Two tropoelastin-binding peptides (Gd-DOTA)-VVGSPSAQDEASPLS and K(Gd-DOTA)YPDHVQYTHY were tested. In vitro binding studies were performed using Europium-labeled peptides and a DELFIA method. In vivo MRI of the aortic and brachiocephalic arteries was performed in atherosclerotic ApoE-/- and control mice using a 3T Philips Achieva scanner and a single loop microscopy surface coil. Images were acquired for up to 1h after intravenous administration of 0.2 mmol/kg tropoelastin-binding probes. 3D gradient-echo DE-MRI images were acquired with FOV=30x8x30mm, matrix=300, resolution=0.1x0.1mm, slice thickness=0.25mm, TR/TE=27/8ms, TR between subsequent IR pulses=1000ms, and flip angle=30°. T1 mapping was performed using a 3D modified Lock-Locker sequence FOV=22x8x36, matrix=180x171, resolution=0.2x0.2, slice thickness=0.5mm, TR/TE= 9.2/4.7ms, flip angle=10°. T1 values were computed on a pixel-by-pixel basis using an in-house Matlab algorithm.
We developed of a new gadolinium-based tropoelastin-binding contrast agent for imaging atherosclerosis. Both peptide-based probes showed promising pharmacokinetics, specificity and sensitivity for in vivo MRI imaging diseased brachiocephalic arteries in ApoE-/- mice. Further development of such contrast agent may allow for molecular imaging of impaired elastogenesis that accompany atherosclerotic plaque development and plaque vulnerability.
British Heart Foundation (RG/12/1/29262).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.